Key Takeaways: AI-assisted inventions are patentable under U.S. law, but only a person can be named as an inventor. The legal standard is the same regardless of whether AI was…
In a recent article published in Law360, Knobbe Martens lawyers Joshua Martineau and Jarom Kesler explore the U.S. Patent and Trademark Office (USPTO)’s latest guidance regarding ex parte reexamination (EPR)…
Key Takeaway: The USPTO’s new PIER Pilot Program requires applicants in selected PCT national stage applications to affirmatively decide whether to proceed with, delay, or abandon U.S. patent examination. Participation…
Key Takeaway: In a precedential decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., USPTO Director Squires denied IPR institution and reinforced the policy framework for discretionary denial at the…
Key Takeaway: Taylor Swift’s recent trademark filings for her voice and likeness point to a growing trend among celebrities and high-profile individuals using federal trademark law—rather than relying solely on…
In an article published by nonprofit educational medtech incubator Fogarty Innovation, Knobbe Martens partner Kregg Koch shared practical strategies for medtech companies and entrepreneurs looking to protect and maximize the…
In their recent Sports Business Journal article, Knobbe Martens lawyers Jonathan Hyman, Jonathan Menkes, and Edward Nester examine a growing IP challenge in the sports industry: what happens when an…
In a recent Reuters Westlaw article, Knobbe Martens lawyers Yi Zhou and Ben Katzenellenbogen discuss the Federal Circuit’s decision in USAA v. PNC Bank and its implications for patent eligibility…
In the latest installment of their monthly Law360 column covering recent noteworthy Federal Circuit decisions, Knobbe Martens partners Sean Murray and Jeremiah Helm discussed the court’s opinion on retroactivity in…
Key Takeaway: The U.S. Patent and Trademark Office’s April 30, 2026 memorandum encourages patent applicants to submit separate declarations supporting “subject matter eligibility” (SMEDs) in response to § 101 rejections….
